Last reviewed · How we verify
LY4268989
At a glance
| Generic name | LY4268989 |
|---|---|
| Also known as | MORF-057 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4268989 (MORF-057) in Healthy Participants (PHASE1)
- LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC (PHASE2)
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (PHASE2)
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |